The persistent efficacy of doramectin pour-on against biting and sucking louse infestations of cattle.
A repeated-exposure challenge model was used to evaluate the pour-on formulation of doramectin in preventing the establishment of louse infestations in cattle. Twenty calves cleared of preexisting biting and sucking louse infestations were randomly and equally allocated to either a doramectin-treated or untreated control group, with five replicates per group. Doramectin pour-on was administered topically at a dose rate of 500 microg/kg body weight. Every 14 days, from a pool of seeder calves with infestations of at least 50 biting and 50 sucking lice each, 10 calves were selected and 1 was placed in each replicate pen. Every week during the 112-day study, 9 predilection sites on the doramectin-treated and untreated calves were examined to estimate the louse population density. A calf met the infestation criterion for a louse species when two or more live lice were counted on two or more body regions for two consecutive count days. Because only 4 of 10 untreated calves acquired Solenopotes capillatus infestations, the persistent efficacy of doramectin against S. capillatus was not evaluated. Bovicola bovis and Linognathus vituli infestations in the untreated calves developed shortly after exposure to infested seeder calves. The acquisition of B. bovis and L. vituli infestations in the doramectin-treated group was delayed for 77 days and 105 days, respectively.
Skogerboe
T L
TL
Pfizer Animal Health Group, Lee's Summit, MO 64081-2998, USA. skoget@pfizer.com
Smith
L L
LL
Karle
V K
VK
Derozier
C L
CL
D000287:Administration, Topical; D000818:Animals; D000854:Anoplura / Q000254:growth & development*; D002417:Cattle; D002418:Cattle Diseases / Q000188:drug therapy / Q000517:prevention & control*; D004006:Dichlorvos / Q000627:therapeutic use; D005260:Female; D007306:Insecticides / Q000008:administration & dosage / Q000494:pharmacology* / Q000627:therapeutic use; D007559:Ivermectin / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000494:pharmacology; D010373:Lice Infestations / Q000188:drug therapy / Q000517:prevention & control*; D008297:Male; D008003:Phthiraptera / Q000254:growth & development*; D011897:Random Allocation; D014922:Wisconsin
D007306:Insecticides; D007559:Ivermectin; D004006:Dichlorvos; C084101:doramectin